China Resources Pharmaceutical Group Limited (CHINARES PHARMA) filed its Monthly Return for the period ended 31 March 2026, showing no movements in share capital during the month.

• Issued Shares: The company closed March with 6.28 billion ordinary shares in issue, identical to the level at the end of February. No treasury shares were held or created.

• Public Float: Management confirmed compliance with the Hong Kong Stock Exchange’s 25 percent minimum public float requirement.

• Share Option Scheme: – Outstanding options: 0 – Remaining option pool: 628.45 million shares available for future grants under the scheme approved on 12 December 2017. – No new shares were issued and no treasury shares were transferred during the month.

• Capital Instruments: The filing recorded no warrants, convertible securities, or other agreements that could affect share capital, and no repurchases or cancellations occurred.

Overall, CHINARES PHARMA’s equity structure remained stable in March, with sufficient headroom preserved under its existing share option mandate and full adherence to listing rules on public float.